AXIN1 and hepatocellular carcinoma: We, however, did not detect significantly upregulated levels of TBX3 in either AXIN1- or CTNNB1-mutant cells, which may reflect either a selective advantage for clones with low expression of the anti-proliferative factor TBX3, or variability in TBX3 levels across HCC subtypes (Figure S7E).40